Abstract
Busulfan is an example of a drug eliminated through glutathione S-transferase (GST)-catalyzed conjugation with reduced glutathione (GSH). We studied the pharmacokinetics and toxicity of busulfan in C57BL6 mice in correlation with liver GST activity and GSH synthesis by accurate determination of precursors, namely, γ-glutamyl-cysteine and cysteine. A significantly lower incidence of acute toxicity was observed in mice receiving busulfan 16.5 mg/kg twice a day compared with animals receiving 33 mg/kg once a day. In both cases, a total dose of 132 mg/kg was administered over 4 days. The difference in toxicity was explained by pharmacokinetics since a strong induction of clearance was observed only in animals treated twice daily. Induction of metabolism was correlated with an increase in liver cysteine content and enhanced glutathione synthesis rate, whereas GST activity was unchanged. To our knowledge, this is the first time that in vivo flux of GSH synthesis has been shown to be closely related to a drug plasma clearance and toxicity. These results allow hypothesizing that GSH liver synthesis may directly influence busulfan clearance in humans with possible implications in the occurrence of hepatic veno-occlusive disease.
Footnotes
-
This work was supported by Association de la Recherche sur le Cancer, Académie Nationale de Médecine, Institute Gustave Roussy, and Centre National de la Recherche Scientifique, Ligue contre le Cancer, and Paris XI University.
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.106.012880.
-
ABBREVIATIONS: GSH, reduced glutathione; AUC, area under concentration-time curve; BMT, bone marrow transplantation; CL/F, clearance uncorrected for bioavailability; GCS, γ-glutamyl-cysteine synthetase; F, bioavailability; GC, gas chromatography; GST, glutathione S-transferase; ke, terminal phase elimination rate constant; LC, liquid chromatography; MS, mass spectrometry; MS/MS, tandem mass spectrometry; THT, tetrahydrothiophene; THT+, sulfonium ion of glutathione; t1/2, half-life.
- Received September 11, 2006.
- Accepted November 17, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|